EP1185558A1 - Peptide having preptin functionality - Google Patents
Peptide having preptin functionalityInfo
- Publication number
- EP1185558A1 EP1185558A1 EP00942575A EP00942575A EP1185558A1 EP 1185558 A1 EP1185558 A1 EP 1185558A1 EP 00942575 A EP00942575 A EP 00942575A EP 00942575 A EP00942575 A EP 00942575A EP 1185558 A1 EP1185558 A1 EP 1185558A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pro
- preptin
- asp
- analog
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101800001717 Preptin Proteins 0.000 title claims abstract description 223
- 102100025947 Insulin-like growth factor II Human genes 0.000 title claims abstract description 222
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 50
- 230000003914 insulin secretion Effects 0.000 claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 230000000975 bioactive effect Effects 0.000 claims abstract description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 92
- 102000004877 Insulin Human genes 0.000 claims description 48
- 108090001061 Insulin Proteins 0.000 claims description 48
- 229940125396 insulin Drugs 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 36
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 30
- 239000008103 glucose Substances 0.000 claims description 30
- 108010089198 phenylalanyl-prolyl-arginine Proteins 0.000 claims description 26
- NTUPOKHATNSWCY-PMPSAXMXSA-N (2s)-2-[[(2s)-1-[(2r)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=CC=C1 NTUPOKHATNSWCY-PMPSAXMXSA-N 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 21
- RGYCVIZZTUBSSG-JYJNAYRXSA-N Tyr-Pro-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O RGYCVIZZTUBSSG-JYJNAYRXSA-N 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- MHZXESQPPXOING-KBPBESRZSA-N Gly-Lys-Phe Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MHZXESQPPXOING-KBPBESRZSA-N 0.000 claims description 17
- 101500026260 Rattus norvegicus Preptin Proteins 0.000 claims description 16
- 108010073025 phenylalanylphenylalanine Proteins 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 230000028327 secretion Effects 0.000 claims description 14
- 101500026336 Homo sapiens Preptin Proteins 0.000 claims description 13
- 150000001413 amino acids Chemical group 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 13
- MNMYOSZWCKYEDI-JRQIVUDYSA-N Tyr-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MNMYOSZWCKYEDI-JRQIVUDYSA-N 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 11
- 238000003556 assay Methods 0.000 claims description 11
- 101500026263 Mus musculus Preptin Proteins 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 claims description 5
- 238000003149 assay kit Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000013060 biological fluid Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 108010015792 glycyllysine Proteins 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 108010020532 tyrosyl-proline Proteins 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- IPTUBUUIFRZMJK-ACRUOGEOSA-N Lys-Phe-Phe Chemical compound C([C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 IPTUBUUIFRZMJK-ACRUOGEOSA-N 0.000 claims description 3
- OYEUSRAZOGIDBY-JYJNAYRXSA-N Pro-Arg-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OYEUSRAZOGIDBY-JYJNAYRXSA-N 0.000 claims description 3
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 claims description 3
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KCOPOPKJRHVGPE-AQZXSJQPSA-N Asp-Thr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O KCOPOPKJRHVGPE-AQZXSJQPSA-N 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 claims 30
- BKVICMPZWRNWOC-RHYQMDGZSA-N Thr-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O BKVICMPZWRNWOC-RHYQMDGZSA-N 0.000 claims 27
- 108010057821 leucylproline Proteins 0.000 claims 26
- CJZTUKSFZUSNCC-FXQIFTODSA-N Pro-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 CJZTUKSFZUSNCC-FXQIFTODSA-N 0.000 claims 24
- LDEBVRIURYMKQS-WISUUJSJSA-N Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO LDEBVRIURYMKQS-WISUUJSJSA-N 0.000 claims 5
- 238000010324 immunological assay Methods 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 claims 1
- ZOCJFNXUVSGBQI-HSHDSVGOSA-N Thr-Trp-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O ZOCJFNXUVSGBQI-HSHDSVGOSA-N 0.000 claims 1
- QZOSVNLXLSNHQK-UWVGGRQHSA-N Tyr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QZOSVNLXLSNHQK-UWVGGRQHSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical group [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 32
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 9
- 229960001031 glucose Drugs 0.000 description 29
- 241000700159 Rattus Species 0.000 description 20
- 239000008187 granular material Substances 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000003127 radioimmunoassay Methods 0.000 description 17
- 238000004007 reversed phase HPLC Methods 0.000 description 16
- 108010074605 gamma-Globulins Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 210000000496 pancreas Anatomy 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 13
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 239000005556 hormone Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 8
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 7
- 108010067035 Pancrelipase Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000000763 evoking effect Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 210000004739 secretory vesicle Anatomy 0.000 description 6
- 229920002527 Glycogen Polymers 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 2
- 102000009133 Arylsulfatases Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 2
- 102000006732 Citrate synthase Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- 101710186630 Insulin-1 Proteins 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108060007951 sulfatase Proteins 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- NTFTULBKHJJQAW-HNNXBMFYSA-N 9h-fluoren-9-ylmethyl n-[(2s)-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C=O)C3=CC=CC=C3C2=C1 NTFTULBKHJJQAW-HNNXBMFYSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- WYBVBIHNJWOLCJ-IUCAKERBSA-N Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N WYBVBIHNJWOLCJ-IUCAKERBSA-N 0.000 description 1
- 241000370685 Arge Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BHQQRVARKXWXPP-ACZMJKKPSA-N Asn-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N BHQQRVARKXWXPP-ACZMJKKPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- MWAJSVTZZOUOBU-IHRRRGAJSA-N His-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC1=CN=CN1 MWAJSVTZZOUOBU-IHRRRGAJSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- ADHNYKZHPOEULM-BQBZGAKWSA-N Met-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O ADHNYKZHPOEULM-BQBZGAKWSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 102400000203 Pancreastatin Human genes 0.000 description 1
- 101800005322 Pancreastatin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- IPVPGAADZXRZSH-RNXOBYDBSA-N Phe-Tyr-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IPVPGAADZXRZSH-RNXOBYDBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000738583 Senna artemisioides Species 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000022001 negative regulation of insulin secretion Effects 0.000 description 1
- 230000002644 neurohormonal effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- RYZUEKXRBSXBRH-CTXORKPYSA-N pancreastatin Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)C1=CN=CN1 RYZUEKXRBSXBRH-CTXORKPYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029537 positive regulation of insulin secretion Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to a bioactive peptide.
- it relates to a peptide secreted by the pancreatic islet ⁇ -cell that stimulates insulin secretion.
- Pancreatic islet ⁇ -cells play a major regulatory role in physiology, mainly through their secretion of insulin, a peptide hormone which exerts profound effects on intermediary metabolism (Draznm et al (1994))
- a second ⁇ -cell hormone, amylin may also cont ⁇ bute to ⁇ -cell regulatory function through its actions on insulin secretion and tissue insulin sensitivity (Cooper, G ( 1994); Hettiarachchi et al (1997)).
- hormones are packaged in secretory granules, which undergo regulated release in response to signals such as fuels (eg. glucose, ammo acids) or neurohormonal stimuli.
- fuels eg. glucose, ammo acids
- neurohormonal stimuli e.g. glucose, ammo acids
- These granules contain dense cores ⁇ ch in insulin and Zn, while smaller amounts of insulin C-peptide, amylin, promsuhn, chromogramn- de ⁇ ved peptides, proteases and other proteins are found in the granule matrix (Hutton, J ( 1989)).
- pancreatic islet ⁇ -cells secrete yet a further regulatory peptide.
- this peptide enhances glucose-mediated insulin secretion.
- the present invention provides the peptide preptin or an analog thereof.
- preptin a peptide of 34 ammo acids, the sequence of which is as follows.
- R 2 is Gin or Pro; Rs is Ala or Thr; t is Asp or Asn;
- Rs is Gin or Lys
- Re is Tyr or Phe
- R7 is Arg or Lys; Rs is Ala or Thr; and or an analog thereof.
- the invention provides human preptin having the amino acid sequence:
- the invention provides rat preptin having the amino acid sequence:
- the invention provides mouse preptin having the amino acid sequence:
- amino acid sequence corresponds to Asp69-Leu ⁇ o 2 of the proIGF-II E-peptide in each mammal.
- the present invention provides a polynucleotide which encodes preptin or an analog thereof.
- the invention provides a vector or cell-line which includes a polynucleotide which encodes preptin or an analog thereof and which is capable of expressing preptin or said analog.
- Preptin salts which are preferably physiologically acceptable, are also provided.
- the invention further provides a pharmaceutical composition which comprises preptin or an analog thereof, or preptin salts.
- the invention provides a method of stimulating insulin secretion for a therapeutic or prophylactic purpose which comprises the step of administering to a patient in need of such therapy or prophylaxis an effective amount of preptin or an analog thereof.
- the invention provides the use of preptin or an analog thereof or a salt thereof in the preparation of a medicament, particularly for stimulating insulin secretion.
- the invention provides a method of modulating glucose mediated insulin secretion which comprises the step of administering to a patient an effective amount of preptin, a preptin analog, a preptin agonist or a preptin antagonist.
- the invention provides antibodies which bind preptin or its analogs, assays which employ such antibodies and assay kits which contain such antibodies.
- Figure 1 shows purification and characterisation of preptin.
- Figure 2 shows cellular preptin secretion, a) Preptin R1A standard curve, b) RIA charactensation of preptm-hke immunoreactive matenal (PLIM) in RP-HPLC fractions of 24-h ⁇ TC6-F7 conditioned medium and mtra-granular fractions from Figure lb. c) MALDI-TOF MS of the major PLIM containing fraction secreted from ⁇ TC6-F7 cells. Peak corresponds to munne preptin (M + H + ) with 0.07% error.
- PLIM preptm-hke immunoreactive matenal
- FIG 4 shows the immunohistochemistry of munne pancreas.
- Pancreas harvested from adult FVB/n mice was sectioned and stained with haematoxylin and polyclonal rabbit antisera using lmmunoperoxidase-conjugated goat-anti-rabbit second antibody.
- Figure 5 shows the RIA characterisation of preptin-like immunoreactive material (PLIM) in RP-HPLC fractions from rat islets or ⁇ TC6-F7 granule fractions (standard; Fig. lb).
- PLIM prept
- Figure 6 shows preptin and insulin co-secretion from ⁇ TC6-F7 cells and isolated rat islets.
- a,b Glucose-mediated co-secretion of preptin with insulin from a, ⁇ TC6-F7 cells and b, isolated rat islets.
- Figure 7 shows the effects of preptin on insulin secretion, a, b, Purity and mass of purified a, rabbit anti-rat preptin ⁇ -globulin and b, non-immune rabbit ⁇ -globulin.
- 1 light chain IgG, M + H + ; 2: whole IgG, M + 4H + ; 3: heavy chain IgG, M + H + ; 4: whole IgG, M + 2H + ; whole IgG, M + H + .
- the present invention is directed to a novel peptide which has been found in pancreatic islet ⁇ -cell granules.
- This peptide, preptin has been determined to stimulate glucose-evoked insulin secretion.
- preptin was identified using a single-step density- gradient centrifugal method to purify secretory granules from cultured munne ⁇ TC6-F7 cells with purity being confirmed by marker- protein analysis (Figure la). Insulin was used to track purification of granule-cores, whereas amylin, which is present in the granule- matrix (Johnson, K (1988)), was measured to verify granule-membrane integrity ( Figure la). Soluble granule components were then separated using reversed-phase HPLC (A 2 ⁇ ; Figure lb). Peptide-identity was determined by mass spectrometry and NH 2 - terminal amino-acid sequencing.
- Preptin is flanked NH 2 - terminally by a recognised Arg cleavage-site, and COOH- terminally by a putative dibasic (Arg-Arg) cleavage motif (Bell et at, (1985)) (Fig. le). These residues are highly conserved between species, and are likely to serve as post- translational processing signals.
- amino acid sequence of mouse preptin is as follows:
- Preptin is encoded by polynucleotides having the following nucleotide sequences:
- Preptin may be generated by synthetic or recombinant means.
- preptin may be synthesised using any of the commercially available solid phase techniques such as the Merryfield solid phase synthesis method, where ammo acids are sequentially added to a growing amino acid chain (see Merryfield, J. Am. Soc. 85:2146-2149 ( 1963)).
- Equipment for automative synthesis of peptides is also commercially available from suppliers such as Perkm Elmer/Applied Biosystems, Inc and may be operated according to the manufacturers instructions.
- Preptin may also be produced recombinantly by inserting a polynucleotide (usually DNA) sequence that encodes the protein into an expression vector and expressing the peptide in an appropnate host.
- a polynucleotide usually DNA
- Any of a vanety of expression vectors known to those of ordinary skill m the art may be employed.
- Expression may be achieved in any appropnate host cell that has been transformed or transfected with an expression vector containing a DNA molecule which encodes the recombinant peptides. Suitable host cells include prokaryotes, yeasts and higher eukaryotic cells.
- Vectors and/or cells lines which express preptin have utility in their own nght and also form part of the invention.
- Analogs of preptin and of its encoding polynucleotides are also within the scope of the present invention. Such analogs include functional equivalents of preptm and of the polynucleotides descnbed above. In terms of preptin itself, functional equivalents include all proteins which are immunologically cross-reactive with and have substantially the same function as preptin. That equivalent may, for example, be a fragment of preptin containing from 6 to 33 amino acids (usually representing a C-terminal truncation) and including a preptin active site or sites, a substitution, addition or deletion mutant of preptin, or a fusion of preptin or a fragment or a mutant with other amino acids.
- the six amino acids forming the smallest fragment can be from any part of the sequence, provided they are consecutive in that sequence and fulfil the functional requirement. It is of course also possible (and expressly contemplated) that the bioactive peptide include any one of those hexapeptides, or indeed be or include any heptapeptide, octapeptide, nonapeptide, or decapeptide from the sequence.
- Peptides which are, or include a hexapeptide, heptapeptide, octapeptide, nonapeptide or decapeptide from human preptin are particularly preferred.
- Additions and/or deletions of amino acids may also be made as long as the resulting peptide is immunologically cross-reactive with and has substantially the same function as preptin.
- Equivalent polynucleotides include nucleic acid sequences that encode proteins equivalent to preptin as defined above. Equivalent polynucleotides also include nucleic acid sequences that, due to the degeneracy of the nucleic acid code, differ from native polynucleotides in ways that do not effect the corresponding amino acid sequences. A prediction of whether a particular polynucleotide or polypeptide is equivalent to those given above can be based upon homology. Polynucleotide or polypeptide sequences may be aligned, and percentage of identical nucleotides in a specified region may be determined against another sequence, using computer algorithms that are publicly available.
- Two exemplary algorithms for aligning and identifying the similarity of polynucleotide sequences are the BLASTN and FASTA algorithms.
- the similarity of polypeptide sequences may be examined using the BLASTP algorithm.
- Both the BLASTN and BLASTP software are available on the NCBI anonymous FTP server (ftp://ncbi.nlm.nih.gov) under /blast/execu tables/.
- the BLASTN algorithm version 2.0.4 [Feb-24- 1998] set to the default parameters described in the documentation and distributed with the algorithm, is preferred for use in the determination of variants according to the present invention.
- BLAST family of algorithms, including BLASTN and BLASTP, is described at NCBI's website at URL http://www.ncbi.nlm.nih.gov/BLAST/newblast.html and in the publication of Altschul, Stephen F, et al (1997). "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.
- the computer algorithm FASTA is available on the Internet at the ftp site ftp://ftp.virginia.edu.pub/fasta/.
- Analogs according to the invention also include the homologues of preptin from species other than human, rat or mouse. Such homologues can be readily identified using, for example, nucleic acid probes based upon the conserved regions of the polynucleotides which encode human, rat and mouse preptin.
- Preptin or its analogs can also be present in various degrees of purity.
- the preptin/analog component makes up at least 50% by weight of the preparation, more preferably at least 80% by weight, still more preferably at least 90% by weight, still more preferably at least 95% by weight and yet more preferably at least 99% by weight.
- the preptin or analog be present in a pure or substantially pure form.
- preptin or preptin analogs may also be presented as a pharmaceutical composition.
- Such compositions may comprise preptin or preptin analogs together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic ingredients where desirable.
- the carrier must be acceptable in the sense of being compatible with the preptin or preptin analog and not deleterious to the patient to be treated. Desirably, the composition should not include substances with which peptides are known to be incompatible.
- compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredients into association with a carrier which constitutes one or more accessory ingredients.
- preptin or preptin analogs may be injected parenterally, eg. intravenously into the blood stream of the patient being treated.
- the route can vary, and can be intravenous, subcutaneous, intramuscular, intraperitoneal, enterally, transdermally, transmucously, sustained release polymer compositions (eg. a lactide polymer or co-polymer microparticle or implant), perfusion, pulmonary (eg. inhalation), nasal, oral, etc.
- compositions suitable for parenteral and in particular intravenous administration are presently preferred.
- Such compositions conveniently comprise sterile aqueous solutions of preptin or the preptin analog.
- the solutions are isotonic with the blood of the patient to be treated.
- Such compositions may be conveniently prepared by dissolving the preptin or analog in water to produce an aqueous solution and rendering this solution sterile.
- the composition may then be presented in unit or multi-dose containers, for example sealed ampoules or vials.
- compositions suitable for sustained release parenteral administrations are also well known in the art. See, for example, US Patent ⁇ os. 3,773,919 and 4,767,628 and PCT Publication No. WO 94/ 15587.
- preptin it is also convenient for preptin to be converted to be in the form of a salt.
- a salt will generally be physiologically acceptable, and can be formed using any convenient art standard approach.
- Preptin salts formed by combination of preptin with anions of organic acids are particularly preferred.
- Such salts include, but are not limited to, malate, acetate, propionate, butyrate, oxaloacetate, citrate, isocitrate, ⁇ -ketoglutarate, succinate, fumarate and trifluoroacetate salts.
- the salts this formed can also be formulated into pharmaceutical compositions for therapeutic administration where this is desired.
- Granule purification ⁇ -cells at passages 55-60 from 8- 12 triple flasks were harvested by trypsinization, yielding on average 2.5-4.0 ml of pure cells (1.6 - 2.4 x 10 9 ), which then were concentrated (1700 x g, 5 min), washed twice with PBS, and once with Homogenisation Medium (0.3 M sucrose/ 10 mM MES K (Sigma) /l mM K 2 EGTA/ 1 mM Mg2S0 /pH 6.5), then homogenised on ice in the same medium at 1 :5 (v/v).
- Homogenisation Medium 0.3 M sucrose/ 10 mM MES K (Sigma) /l mM K 2 EGTA/ 1 mM Mg2S0 /pH 6.5
- Solutions (v/v) of 13% and 31% OptiPrepTM (Nycomed) were prepared by dilution with Homogenisation Medium, and 6 x 10 ml continous gradients (31%- 13% OptiPrep) poured (Auto Densi-Flow II, Haakebuchler) into Ultra- Clear tubes (Beckman).
- Integrity of granule preparations was monitored using radioimmunoassays for insulin (crystalline granule core), amylin (granule matrix); purity by functional assays for aryl sulphatase (lysosomes) and citrate synthase (mitochondria) ; and total protein content using Bicinchoninic acid (Pierce) .
- Granule proteins were purified in two sequential RP-HPLC runs (A: 0.08% TFA v/v; B: 80% acetonitrile with 20% A; Applied Biosystems 140B/785A/ 1 12A system;
- Secretory granule material was initially centrifuged ( 16,000 x g, 20 min) before loading. An initial 15 min isocratic step was employed, and sequential 30s fractions collected from 19 min post-injection. Slightly different gradients were used sequentually to purify proteins; the first semi-purified granule proteins, whereas the second was slightly flatter, to increase resolution and purity.
- Purified peptides were identified by N-terminal sequence determination (automated Edman method; ABI ProciseTM) combined with accurate mass determination by MALDI-TOF MS. For complete sequence verification, purified mouse preptin isolates were cleaved using Lys-C (Boehringer Mannheim), and the resulting peptide fragments repurified by RP-HPLC.
- Peptide molecule weights were determined by MALDI-TOF MS (Hewlett-Packard G2025A; 337 nm-emission nitrogen laser/ 150 ⁇ j maximum output/3 ns pulsewidth/30 kV ion acceleration potential) fitted with a 500 MHz digital oscilloscope (G2030AA, LeCroy) using an -CHC matrix with recombinant human insulin ( ⁇ ovo ⁇ ordisk; M + H + , 5808.66 Da; M + 2H + , 2904.83) and somatostatin (Bachem; M + H + , 1638.91 , M + ⁇ a + , 1660.90) mass standards.
- MALDI-TOF MS Hewlett-Packard G2025A; 337 nm-emission nitrogen laser/ 150 ⁇ j maximum output/3 ns pulsewidth/30 kV ion acceleration potential
- MS was performed under high vacuum ( ⁇ 1.0 ⁇ Torr) and data acquired (ChemStation; 0-20PS method positive polarity in the 0-20 kDa range) with external mass calibration in "single shots" mode. Accurate molecular weights of purified peptides were confirmed by interpolation with external mass standardisation.
- Rat preptin was chemically synthesised (Auspep Pty, Australia), according to the predicted sequence, using Fmoc chemistry on an Advanced Chem Tech 396 Robotics Peptide Synthesiser starting with FmocLeu- Wang resin.
- the peptide was deprotected and cleaved from the resin with a solution of 92.5% TFA: 2.5% water:2.5% triisopropylsilane: 2.5% dithiothreitol for 3 h.
- the peptide was precipitated from the TFA solution by addition of diisopropyl ether and the precipitate dissolved in 30% acetonitrile: water, lyophilised, and purified by RP- HPLC. Purity was confirmed as >99% by analytical RP-HPLC (rat preptin eluted at 47% B), while MALDI-TOF MS validated the mass as 3932.4 Da + 0.026%.
- Synthetic rat preptin was conjugated to the carrier, ovalbumin, using the single step glutaraldehyde method at pH 7.0, then used to raise polyclonal antisera in NZW rabbits.
- Preptin was 125 I-radiolabelled using the chloramine-T method, and [ 12 I)preptin (362 ⁇ Ci/ ⁇ g) purified by Sephadex G- 10 chromatography (50 mM phosphate buffer, pH 7.5). An optimised RIA for preptin was then developed, with B/F separation by the PEG-assisted second antibody (goat- anti- rabbit method).
- Preptin secretion was studied in ⁇ TC6-F7 cells (passage #52), cultured otherwise as above in 24-well plates at 4 x 10 5 cells per well. Preptin stimulation was performed after 3 d growth, at 80% confluence. Cells were washed twice in HEPES-buffered KRB before commencement of secretion studies, then preincubated for 1 h in 1 ml/well incubation buffer (0 mM glucose; 0. 1% w/w Fraction V BSA (Sigma) dissolved in HEPES-KRB) 500 ⁇ l/well was then removed, and replaced with an equivalent volume of fresh incubation buffer containing various concentrations of glucose.
- preptin-like immunoreacti ⁇ e material Since preptin is a cleavage product of the E-peptide of IGF-II, and other cleavage products from a similar region have been isolated from serum in the past (Hylka (1985); Daughaday ( 1992); Liu ( 1993)), quantitation by preptin RIA was insufficient to characterise the nature of the secreted and circulating peptide.
- a combined RP- HPLC/preptin RIA method was therefore developed to further characterise PLIM.2 ml aliquots of separated plasma from a human donor, and ⁇ TC6-F7 conditioned medium, were acidified with 0.1 ml of 4M acetic acid and applied to a C- 18 Sep Pak (Waters, 1 ml volume) which had been pre-equilibrated with 10 ml of 100% methanol and 20 ml of 4% (v/v) acetic acid.
- peripheral tissues including skeletal muscle.
- preptin to alter glucose uptake and incorporation into muscle glycogen was investigated using isolated incubated stripped soleus muscle as a model tissue. All animal methods were carried out with appropriate permission from the Institutional Animal Ethics Committee.
- 18-h fasted rats were anaesthetised (45 mg/kg Pentobarbitone sodium) then sacrificed by cervical dislocation, and soleus mucles dissected under carboxygenated-KHB (O2:C0295: 5 v/v), then incubated in nDMEM supplemented with various concentrations of insulin and preptin. Muscles were teased longitudinally into 3 equal strips with a final radius of approximately 1.5 mm [(U) 14 C] D(+)-glucose ( 1 mCi/ml, Amersham) was diluted 1 : 20 (v/v) in 70% ethanol to yield a final concentration of 0.5 ⁇ Ci/ 10 ⁇ l.
- Actrapid® Recombinant Human Insulin 100 U/ml, ⁇ ovo ⁇ ordisk was diluted 1/ 1000 in 10 ml nDMEM.
- 60 ⁇ g rat preptin was dissolved in 1526 ⁇ l of nDMEM to a concentration of 10 ⁇ M, then further diluted in nDMEM to give stock solutions of 1 ⁇ M, 100 nM, 10 nM, 100 pM and 1 pM.
- Two different experimental paradigms were employed to determine whether preptin (i) stimulated the rate of glucose incorporation into glycogen, or (ii) acted as an antagonist of insulin-evoked glucose incorporation into glycogen.
- Preptin agonist protocol All methods were as described above, except that strips were incubated in the absence of insulin (except for the positive control, at 23.7 nM) and final preptin concentrations of 0, 0.1, 1 , 10 and 100 nM. Effect of preptin on insulin secretion
- Insulin and amylin are known to modulate ⁇ -cell insulin secretion via presumed autocnne mechanisms.
- the effect of preptin on insulin secretion was therefore tested using a ⁇ -cell secretagogue protocol ⁇ TC6-F7 cells were subcultured at passage #52 into 24- well plates at 4 x 10 5 cells/well.
- Mouse preptin is a 34 ammo acid peptide which corresponds to Asp69-Leu ⁇ o2 of munne proIGF-II E- peptide
- Preptin was present in granules at 1 :8 the content of insulin, but 2: 1 that of amylin (mol/mol), as determined by integration of RP-HPLC peak- areas.
- Preptin is flanked NH 2 -term ⁇ nally by a recognised Arg cleavage site, and COOH-terminally by a putative dibasic (Arg-Arg) cleavage motif (Bell ( 1984)) ( Figure le). These residues likely serve as post-translational processmg signals, and are highly conserved between species Many prohormone precursors incorporate more than one hormone with differential proteolytic processing often being tissue specific (Martinez ( 1989)). The above results indicated that proIGF-II is a prohormone with more than one peptide- hormone product.
- IGF-II is a member of the insulin family that regulates cell growth, differentiation and metabolism (De Chiara et al (1990). It is a single polypeptide chain denved from the BCA and D domains of proIGF-II (see Figure le) and is widely synthesised in fetal and adult tissues. Insulin expression, on the other hand, is almost completely confined to ⁇ -cells. In mammalian genomes, the IGF-II gene is contiguous with those of insulin (Bell ( 1985)) and recent studies in humans have identified a V ⁇ TR polymorphism upstream of the INS and IGF-II genes, which may contribute to differential regulation of both genes (Ong ( 1999)).
- preptin is synthesised in islet ⁇ -cells and packaged in secretory granules. Further, it is co-secreted with insulin in a glucose-dependent manner.
- insulin secretion may be modulated by islet ⁇ -cell hormones, including insulin (Kulkami ( 1999); Elahi ( 1982); Argoud ( 1987)), amylin (Waggoner et al (1993); Silvestre ( 1996); Degano et al ( 1993)), and pancreastatin (Tatemoto (1986)).
- insulin Kulkami ( 1999); Elahi ( 1982); Argoud ( 1987)
- amylin Waggoner et al (1993); Silvestre ( 1996); Degano et al ( 1993)
- pancreastatin Tatemoto (1986)
- preptin is a physiological regulator of insulin secretion, which acts in a newly recognised feed-forward autocnne loop to enhance glucose-stimulated insulin secretion, and may function to counterbalance the inhibitory effects of other ⁇ -cell hormones on insulin secretion.
- preptin acts to recruit, pnme and co-ordinate the glucose-responsive activity of ⁇ -cells m a local manner, amplifying the glucose- evoked signal to the ⁇ -cell organ. This action would be similar to the feed-forward mechanism effected in platelets by the thrombm- elicited release of thromboxane A2 (Barntt ( 1992)).
- preptin biology will be important in type 2 diabetes melhtus, which is charactensed by a complex impairment of msulm secretion (De Fronzo et al ( 1992)).
- a defect in preptin synthesis, secretion, or action could contnbute to the defective glucose-mediated msulm secretion in this condition and preptin administration may be advantageous for the treatment of type 2 diabetes melhtus or other disorders associated with diminished ⁇ -cell insulin secretion.
- V ⁇ TR vanable number of tandem repeat polymorphism upstream of the adjacent insulin (INS) and IGF-II genes regulates expression of both genes, and is associated with an increased tendency to both type 2 diabetes melhtus and polycystic ovary syndrome.
- Section B Preptin is co-packaged with insulin in islet tissue
- PLIM Preptin-like immunoreactive material
- insulin-like immunoreactive material were co-localised in islet ⁇ -cells (Figs. 4a,b).
- Competition studies showed that PLIM-staining was suppressed by pre-incubating preptin antiserum with synthetic preptin in a concentration dependent manner (Figs. 4b-d).
- Pancreatic islets were isolated from normal adult male Wistar rats, and the contents extracted with acid ethanol according to a modification of published methods (Wollheim and Sharp ( 1981), Romanus ( 1988)).
- preptin levels were much lower than in ⁇ TC6-F7 cells, the major peak of PLIM co-eluted with intra-granular preptin, indicating that preptin is the dominant physiological component of PLIM in normal islets (Fig. 5).
- Pancreases were perfused with KHB supplemented with 4% dextran, 0.5% BSA, 3 mM-arginine and 5.5 mM glucose (final concentrations). Perfusate was gassed with a mixture of 95% U2/5% CO2 and infused by peristaltic pump at 2.7 ml.min 1 without re-circulation. Pancreases were perfused and equilibrated for 20-min prior to each 70-min perfusion.
- Isolated perfused pancreases were infused with anti-preptin or control ⁇ -globulin and subjected to square-wave stimulation by 20 mM glucose (Fig. 7d).
- preptin is a previously unknown, pancreatic islet ⁇ -cell hormone. It is produced from the E-peptide of pro-IGF-II, is present in islet ⁇ -cell granules in significant amounts, is co-secreted with insulin in a regulated manner, enhances glucose-stimulated insulin secretion, and may act in a feed-forward autocrine loop, probably via binding to a ⁇ -cell surface receptor.
- the present invention provides preptin (including in its human, rat and mouse forms) and analogs of preptin.
- Preptin and its analogs play a physiological role in the stimulation of glucose evoked insulin secretion.
- the invention therefore also provides methods by which glucose-evoked insulin secretion can be modulated.
- modulation will usually involve administration of preptin and its analogs as described above.
- modulation can also be achieved by use of preptin agonists and antagonists.
- a preptin agonist is a compound which promotes or potentiates the effect of preptin on insulin secretion.
- a preptin antagonist is a compound which competes with preptin or otherwise interacts with preptin to block or reduce the effect of preptin on insulin secretion.
- Preptin agonists and preptin antagonists can be identified by assay systems which measure the effect preptin has on insulin secretion in the presence and absence of a test compound.
- assay systems which measure the effect preptin has on insulin secretion in the presence and absence of a test compound.
- the assay systems described in the experimental section herein can be used.
- the agonist/ antagonist can be administered as a pure compound or formulated as a pharmaceutical composition as described above for preptin.
- immunological reagents which bind preptin.
- Such reagents (which can be polyclonal antibodies) can be generated using art standard techniques, including those described in the experimental section.
- Monoclonal antibodies can also be provided. Such antibodies will typically be made by standard procedures as described, eg. in Harlow and Lane 1988. Briefly, appropriate animals are selected and the desired immunisation protocol followed. After the appropriate period of time, the spleens of such animals are excised and individual spleen cells fused, typically, to immortalised myeloma cells under appropriate selection conditions. Thereafter, the cells are clonally separated and the supernatants of each clone tested for the production of an appropriate antibody specific for the desired region of the immunising antigen. Other suitable techniques for preparing antibodies involve in vitro exposure of lymphocytes to the antigen or alternatively, to selection of libraries of antibodies in phage or similar vectors. See, for example Huse et al 1989.
- recombinant antibodies may be produced using procedures known in the art. See, for example, US Patent 4,816,567.
- the antibodies may be used with or without modification. Frequently, antibodies will be labelled by joining, either covalently or non-covalently a substance which provides a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in the literature.
- Antibodies as above to preptin can therefore be used to monitor the presence of preptin in a patient or in preptin quantification assays.
- any convenient immunological format can be employed. Such formats include immunohistochemical assays, RIA, IRMA and ELISA assays.
- the assays can be conducted in relation to any biological fluid which does, or should, contain preptin.
- Such fluids include blood, serum, plasma, urine and cerebrospinal fluid.
- kits can contain, in addition, a number of optional but conventional components, the selection of which will be routine to the art skilled worker.
- additional components will however generally include a preptin reference standard, which may be preptin itself or an analog (such as a fragment).
- antibodies such as described above can, if some circumstances, also function as preptin antagonists by binding to preptin and partly or completely interfering with preptin activity.
- a diagnostic or prognostic method will involve detection of mutations in the gene coding for preptin and/or the preptin secretory mechanism.
- Detection can occur using any one of a number of art standard techniques including Single Stranded Confirmation Analysis (Orita et al ( 1989)) or the Amplification Refractory Mutation System (ARMS) as disclosed in European Patent Application Publication No 0 332 435.
- Draznin, B. and LeRoith, D. Molecular biology of diabetes II. Insulin action, effects on gene expression and regulation, and glucose transport (Humana Press Inc., New Jersey ( 1994)).
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ33635999 | 1999-06-18 | ||
NZ33635999 | 1999-06-18 | ||
PCT/NZ2000/000102 WO2000078805A1 (en) | 1999-06-18 | 2000-06-19 | Peptide having preptin functionality |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1185558A1 true EP1185558A1 (en) | 2002-03-13 |
EP1185558A4 EP1185558A4 (en) | 2006-02-15 |
Family
ID=19927343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00942575A Withdrawn EP1185558A4 (en) | 1999-06-18 | 2000-06-19 | Peptide having preptin functionality |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1185558A4 (en) |
JP (1) | JP2003503019A (en) |
CN (1) | CN1296384C (en) |
AU (1) | AU759203B2 (en) |
CA (1) | CA2375207A1 (en) |
HK (1) | HK1042307A1 (en) |
WO (1) | WO2000078805A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018392A1 (en) | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine oxidase: antagonists and inhibitors |
AU2003225442B2 (en) | 2002-03-08 | 2010-02-04 | Philera New Zealand Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
AU2003281842A1 (en) * | 2002-08-01 | 2004-02-23 | Auckland Uniservices Limited | Preptin methods of use |
JP2006500341A (en) * | 2002-08-01 | 2006-01-05 | プロテミックス コーポレイション リミティド | Method for using compound having preptin function |
CA3011023A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Composition comprising triethylenetramine salts for treating tissue damage |
CA2875095C (en) | 2004-07-19 | 2019-09-03 | Philera New Zealand Limited | Synthesis of triethylenetetramines |
WO2006112737A1 (en) * | 2005-04-20 | 2006-10-26 | Protemix Discovery Limited | Vesiculins |
US8691760B2 (en) | 2009-02-02 | 2014-04-08 | Ramot At Tel-Aviv University | Peptides, pharmaceutical compositions comprising same and uses thereof |
US8901074B2 (en) | 2010-08-04 | 2014-12-02 | Ramot At Tel-Aviv University | Methods of treating autoimmune diseases of the central nervous system (CNS) and neurodegenerative diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986000619A1 (en) * | 1984-07-13 | 1986-01-30 | Chiron Corporation | Prepro insulin-like growth factors i and ii |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8720115D0 (en) * | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
AU631112B2 (en) * | 1988-01-11 | 1992-11-19 | Amylin Corporation | Treatment of type 2 diabetes mellitus |
AU620727B2 (en) * | 1989-07-10 | 1992-02-20 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and essential hypertension and related disorders |
US5234906A (en) * | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
-
2000
- 2000-06-19 AU AU57178/00A patent/AU759203B2/en not_active Ceased
- 2000-06-19 JP JP2001505563A patent/JP2003503019A/en active Pending
- 2000-06-19 CA CA002375207A patent/CA2375207A1/en not_active Abandoned
- 2000-06-19 EP EP00942575A patent/EP1185558A4/en not_active Withdrawn
- 2000-06-19 WO PCT/NZ2000/000102 patent/WO2000078805A1/en active Application Filing
- 2000-06-19 CN CNB008087857A patent/CN1296384C/en not_active Expired - Fee Related
-
2002
- 2002-05-11 HK HK02103568.4A patent/HK1042307A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986000619A1 (en) * | 1984-07-13 | 1986-01-30 | Chiron Corporation | Prepro insulin-like growth factors i and ii |
Non-Patent Citations (13)
Title |
---|
BUCHANAN C M ET AL: "Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion." THE BIOCHEMICAL JOURNAL. 1 DEC 2001, vol. 360, no. Pt 2, 1 December 2001 (2001-12-01), pages 431-439, XP002359658 ISSN: 0264-6021 * |
DUGUAY S.J. ET AL: 'Post-translational Processing of the Insulin-like Growth Factor-2 Precursor. Analysis of O-Glycosylation and Endoproteolysis.' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 29, 17 July 1998, pages 18443 - 18451, XP002159286 * |
GAMMELTOFT S ET AL.: "Insulin-like growth factors and insulin: gene expression, receptors and biological actions." 1989, ELLIS HORWOOD LTD , CHICHESTER , XP009096156 IN: MARTINEZ J (ed.): Peptide Hormones as Prohormones: Processing, Biological Activity, Pharmacology. * page 176 - page 210 * * |
HAGIWARA KOICHI ET AL: "Isolation of a cDNA for a growth factor of vascular endothelial cells from human lung cancer cells: Its identity with insulin-like growth factor II" JAPANESE JOURNAL OF CANCER RESEARCH, vol. 86, no. 2, 1995, pages 202-207, XP009058818 ISSN: 0910-5050 * |
HINTZ R.L. ET AL: 'Development of a radioimmunoassay specific for the E peptide region of insulin-like growth factor II.' CLINICAL RESEARCH vol. 35, no. 3, 1987, XP009096228 * |
HYLKA V.W. ET AL: 'Identification of a peptide fragment from the carboxyl-terminal extension region (E-domain) of rat proinsulin-like growth factor-II.' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 260, no. 27, 25 November 1985, pages 14417 - 14420 * |
PERDUE J F ET AL.: "Development of a specific radioimmunoassayfor E domain containing forms of insulin-like growth factor II." 1991, , NEW YORK , XP009096227 IN: RAIZADA MK, LEROITH D (eds.): "Molecular biology and physiology of insulin, IGFs and their receptors. Advances in experimental and medical biology 293." * page 45 - page 56 * * |
RECHLER M M ET AL: "CHARACTERIZATION OF THE BIOSYNTHETIC PRECURSOR FOR RAT INSULIN-LIKE GROWTH FACTOR II BY BIOSYNTHETIC LABELING RADIOSEQUENCING AND NUCLEOTIDE SEQUENCE ANALYSIS OF A COMPLEMENTARY DNA CLONE" FERAMISCO, J., B. OZANNE AND C. STILES (ED.). CANCER CELLS (COLD SPRING HARBOR), VOL. 3. GROWTH FACTORS AND TRANSFORMATION; MEETING, COLD SPRING HARBOR, N.Y., USA. XVII+450P. COLD SPRING HARBOR LABORATORY: COLD SPRING HARBOR, N.Y., USA. ILLUS. PAPER, 1985, pages 131-138, XP009058812 ISSN: 0-87969-178-6 * |
See also references of WO0078805A1 * |
STEMPIEN M M ET AL: "SEQUENCE OF A PLACENTAL COMPLEMENTARY DNA ENCODING THE MOUSE INSULIN-LIKE GROWTH FACTOR II PRECURSOR" DNA (NEW YORK), vol. 5, no. 5, 1986, pages 357-362, XP009058819 ISSN: 0198-0238 * |
SWOPE S.L. ET AL: 'Bombesin stimulates insuline secretion by a pancreatic islet cell line.' PROC NATL ACAD SCI USA vol. 81, March 1984, pages 1822 - 1826 * |
TATEMOTO K ET AL: "PANCREASTATIN NOVEL PANCREATIC PEPTIDE THAT INHIBITS INSULIN SECRETION" NATURE (LONDON), vol. 324, no. 6096, 1986, pages 476-478, XP001207842 ISSN: 0028-0836 * |
WAEBER G ET AL: "INSULIN SECRETION IS REGULATED BY THE GLUCOSE-DEPENDENT PRODUCTION OF ISLET BETA CELL MACROPHAGE MIGRATION INHIBITORY FACTOR" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 94, 1997, pages 4782-4787, XP000882991 ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000078805A1 (en) | 2000-12-28 |
AU5717800A (en) | 2001-01-09 |
CA2375207A1 (en) | 2000-12-28 |
AU759203B2 (en) | 2003-04-10 |
JP2003503019A (en) | 2003-01-28 |
EP1185558A4 (en) | 2006-02-15 |
HK1042307A1 (en) | 2002-08-09 |
CN1296384C (en) | 2007-01-24 |
CN1355813A (en) | 2002-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102351313B1 (en) | GIP/GLP1 co-agonist compounds | |
US9764004B2 (en) | Glucagon receptor agonists | |
Pittner et al. | Molecular physiology of amylin | |
US7928060B2 (en) | Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them | |
CA2224080C (en) | Relaxin-like factor and methods and uses thereof | |
JPH11501281A (en) | Neuropeptide Y antagonists and agonists | |
US10344068B2 (en) | Natriuretic polypeptides | |
NZ539218A (en) | Synthetic GHRH analogues of 29 amino acids or more | |
AU759203B2 (en) | Peptide having preptin functionality | |
AU2013288383B2 (en) | Popelova, AndreaLipidated peptides as anti-obesity agents | |
US20050026826A1 (en) | Feline proinsulin, insulin and constituent peptides | |
JP4871128B2 (en) | A conformationally constrained parathyroid hormone (PTH) analog | |
Berghman et al. | Immunocytochemistry and immunoblotting of avian prolactins using polyclonal and monoclonal antibodies toward a synthetic fragment of chicken prolactin | |
US20030166561A1 (en) | Peptide | |
Hiejima et al. | Regional distribution and the dynamics of n-decanoyl ghrelin, another acyl-form of ghrelin, upon fasting in rodents | |
EP0341963A3 (en) | Parathyroid hormone antagonists | |
US20030050434A1 (en) | Peptide | |
JP2004512530A (en) | Methods for identifying compounds that modulate muscle mass or muscle function using vasoactive intestinal peptide receptors | |
Jaeger | Long-Acting VIP Analogs | |
Cheloha | Exploration of α/β-peptides as parathyroid hormone receptor ligands and recognition of α/β-peptides by the immune system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011205 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: COOPER, GARTH, JAMES, SMITH Inventor name: BUCHANAN, CHRISTINA, MAREE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PROTEMIX CORPORATION LIMITED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PROTEMIX DISCOVERY LIMITED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/10 20060101ALI20051220BHEP Ipc: C07K 7/04 20060101ALI20051220BHEP Ipc: C07K 14/65 20060101AFI20051220BHEP Ipc: A61K 38/30 20060101ALI20051220BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060103 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1042307 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100105 |